The COPD and asthma devices market size was US$ 37.18 Bn in 2019 and expected to reach US$ 56.79 Bn by 2027; this converts into a compounded annual growth rate (CAGR) of 5.4% for the forecast period.
COPD is the abbreviation for Chronic Obstructive Pulmonary Disease. COPD and asthma devices are generally used for curing respiratory diseases. COPD and asthma are diseases that cause difficulty in breathing and/or create a blockage in the airways of the lungs. Asthma may arise due to mucus production, inflammation and tightening of muscles whereas the primary cause of COPD could be tobacco smoking.
The impact of the pandemic on the COPD & asthma device market has been positive. Since asthma patients are more susceptible to display symptoms of COVID-19, many patients have seemed to improve their adherence to medications. Furthermore, many parts of the world have faced shortages of albuterol inhalers since most of them were used for COVID-19 patients. According to the National Health Services (NHS) in the U.K., the number of inhalers prescribed rose by nearly 70% between February and March 2020.
Drivers: The major driver of the COPD & asthma devices market is the rising air pollution levels. An increase in pollution levels has significantly increased the number of incidences of asthma and COPD. Furthermore, the surge in the population of active smokers also adds to the prevalence of these respiratory diseases and thereby, propelling the market forward. Advancing R&D has led to the improvement in design and as a result, the portability of these devices will aid in the expansion of the market. The rising government initiatives to spread awareness regarding diseases and medication devices are estimated to further boost the market.
Restraints: Increase in price competition and deterioration of material quality is a major restraining factor for the COPD & asthma device market. Incompetent reimbursement support especially in developing countries is further deterring patients from investing in these devices.
Opportunities: Several opportunities, the most important one being the expiration of the patent on blockbuster drugs, will pave the way for the significant expansion of the COPD & asthma device market. The expiration of these drugs will make way for other manufacturers to introduce a lower-priced generic version. This, in turn, may increase the sales of the device. Another factor that holds the potential to drive the market forward is the development of smart inhalers.
1) Recently, in January 2020 Apta Pharma partner with Lupin Ltd. and launched India’s first connected device for metered-dose inhalers called ADHERO.
2) A year ago, in January 2019, FindAir ONE, a smart inhaler device, was launched by FindAir. This device helps patients monitor their condition and predict future attacks.
Classified on the basis of product type, since inhalers are the fastest and most effective method to deliver medication, the segment accounted for the largest market share capturing more than 95% in 2019. The segment is estimated to continue dominating the market throughout the forecast timeline. Nevertheless, the nebulizers segment is projected to register a compound annual growth rate of approximately 5.5%.
The asthma segment, when the market is classified on the basis of indication, led the market to garner around two-thirds in 2019. The rising prevalence of asthma coupled with the surge in awareness among individuals is the major contributor to the segment’s expansion. On the other hand, the COPD segment is predicted to witness a growth rate of around 6% during the forecast period.
Among the distribution channels, the retail pharmacy segment led the market. It accounted for a little under 50% or more than USD 17 billion by the end of 2019. However, the rise of e-commerce and the convenience it brings with it, is making it widely popular among many consumers. This, therefore, is estimated to grow the online pharmacy at a rate of over 7%.
The growing levels of air pollutants in the indoor and outdoor environment are thrusting the North American COPD & asthma devices market. The already high numbers of patients suffering from respiratory disorders coupled with a well-funded R&D sector are estimated to boost the regional market further. All of these factors combined have led the North American market to dominate in 2019. The European market is majorly influenced by the changing lifestyle patterns and comparatively higher air pollution levels. Europe ranked second in terms of market share. Growing population, rapid industrialization, and shift in lifestyle patterns are having a dramatic effect on the COPD & asthma devices market in Asia–Pacific. The region is expected to display the highest growth rate among all other regions.
Some of the key players operating in the COPD and asthma devices market include, but not limited to:
AEROGEN, INC.; ASTRAZENECA PLC; BAXTER INTERNATIONAL INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; 3M COMPANY; GF HEALTH PRODUCTS, INC.; GLAXOSMITHKLINE PLC; KONINKLIJKE PHILIPS N.V. (PHILIPS); NOVARTIS AG; PARI MEDICAL HOLDING GMBH; SMITH’S GROUP PLC.